Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Southwest Pharmaceutical Wins Saridon Trademark Lawsuit

This article was originally published in PharmAsia News

Executive Summary

Southwest Pharmaceutical has received China's Supreme Court verdict, which affirmsthe State Administration for Industry and Commerce's judgment that the firm's Sanlietong trademark is valid. The Supreme Court believed that certain mistakes were committed during the fact-finding and legal application process, so the verdict in the first and second trials should be repealed. This ruling marks the end of a 10-year Saridon trademark lawsuit (PharmAsia News, June 16, 2008) and will have a positive impact for the company. In recent years, pharmaceutical MNCs have been filing suits against Sanlietong, interfering with the company's marketing activities. Even so, the product's revenue for 2008 grew 30 percent to RMB 48 million, reflecting the drug's popularity and potential. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071911

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel